Genetics and Immunology Reproductive Immunology

Antiphospholipid syndrome in pregnancy: a comprehensive literature review

Murvai VR, Galiș R, Panaitescu A, Radu CM, Ghitea TC, Trif P, Onița-Avram M, Vesa AA, Huniadi A

Published March 24, 2025 BMC pregnancy and childbirth, 25(1), 337
DOI 10.1186/s12884-025-07471-w PMID 40128683 PMC PMC11934569

RRM Academy Synopsis

Antiphospholipid syndrome is linked to pregnancy loss and preeclampsia

Antiphospholipid syndrome is linked to repeated pregnancy loss, preeclampsia, and poor fetal growth, according to a 2025 literature review of studies from 2018 to 2024. The review reports that aspirin plus heparin is the standard regimen and improves live birth rates. Other drugs are described for cases that do not respond.

Key Findings

  • The authors screened 847 articles by title and abstract and selected 120 for full-text review, drawn from PubMed searches covering January 2018 to October 2024.
  • Pregnancy complications, with poor fetal growth (fetal growth restriction) as one example, affect 2–8% of pregnancies in developed countries. In obstetric antiphospholipid syndrome the reported range is 12–30% of cases.
  • Preeclampsia occurs in between 10 and 48% of pregnancies with the syndrome, and a European survey of 1000 obstetric cases put fetal loss at approximately 27%.
  • A meta-analysis of 11,000 pregnancies linked anticardiolipin antibodies to fetal growth restriction (odds ratio 2.25) and anti-beta2 glycoprotein 1 antibodies to it (odds ratio 1.31).
  • In a 17-year observational study of 92 pregnancies treated with heparin plus low-dose aspirin, live birth rates were slightly higher with unfractionated heparin (84%) than with low-molecular-weight heparin (79%).

Interpretation

This is a literature review of PubMed sources. The authors favored randomized trials, cohort studies, and systematic reviews. The authors say the right dose of low-molecular-weight heparin in pregnancy for thrombotic antiphospholipid syndrome is not yet definitively established. They add that new drugs need robust clinical validation. The review examines studies of pregnant women. All had the syndrome under international criteria.

RRM Context

Restorative reproductive medicine treats repeated pregnancy loss as a diagnostic question. Antiphospholipid syndrome is a testable cause. Finding it moves a couple from unexplained loss to a diagnosis. The review describes antibody tests repeated at least 12 weeks apart, which belongs to an evaluation that looks for the cause first.

Abstract

Background

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombotic events and adverse obstetric outcomes, particularly in its obstetric form (OAPS). Affecting approximately 0.5% of the population, APS is a leading contributor to recurrent pregnancy loss (RPL), preeclampsia (PE), and fetal growth restriction ((FGR). Despite advancements in understanding its pathophysiology and management, optimal treatment strategies for APS in pregnancy remain challenging and require systematic evaluation. This review synthesizes current evidence on APS mechanisms, diagnostic criteria, and therapeutic interventions, with a focus on maternal and fetal outcomes in OAPS.

Methods

A comprehensive search of PubMed, was conducted to identify studies exploring APS pathogenesis, diagnostic standards, and treatment efficacy in obstetric settings. Inclusion criteria prioritized randomized controlled trials, cohort studies, and systematic reviews with a clear focus on APS and pregnancy.

Results

The review confirmed that APS current accepted pathogenesis is governed by a "two-hit" model, where antiphospholipid antibodies (aPLs) initiate endothelial damage, culminating in thrombosis and placental insufficiency. Epidemiological analysis underscores the prevalence and severity of APS in obstetric contexts, with lupus anticoagulant (LA) emerging as a significant predictor of adverse outcomes. Evidence supports the use of low-dose aspirin (LDA) and heparin to reduce miscarriage rates, while adjunctive treatments, such as hydroxychloroquine (HCQ), have shown promise in improving live birth rates and reducing preterm delivery in high-risk cases. Emerging therapies, including tumoral necrosis factor (TNF-alpha) inhibitors and nitric oxide modulators, may offer additional benefits in refractory cases.

Conclusion

APS remains a critical determinant of adverse pregnancy outcomes, necessitating precise diagnostic criteria and tailored management approaches. This systematic review emphasizes the importance of individualized therapeutic regimens to optimize maternal and fetal health in OAPS and highlights areas for future research, particularly regarding novel pharmacological approaches. Further studies are essential to refine treatment protocols and improve clinical guidelines for managing APS in pregnancy.

Topics

By this author

Related research

Genetics and Immunology › Reproductive Immunology › Antiphospholipid Syndrome and Thrombophilia · Pregnancy › Pregnancy Complications › Hypertensive Disorders · Autoimmune and Inflammatory Disease › Autoimmune Conditions › Systemic Autoimmune Disease
Viorela Romina Murvai, Radu Galiș, Anca Panaitescu, Casandra Maria Radu, Timea Claudia Ghitea, Paula Trif, Miruna Onița-Avram, Alexandra Alina Vesa, Anca Huniadi
V Murvai, R Galiș, A Panaitescu, C Radu, T Ghitea, P Trif, M Onița-Avram, Alex Vesa, A Vesa, A Huniadi
PMID 40128683 40128683 DOI 10.1186/s12884-025-07471-w 10.1186/s12884-025-07471-w Murvai et al. 2025, Murvai 2025